Literature DB >> 26659397

Many men with castrate-sensitive metastatic prostate cancer should not receive chemotherapy.

I F Tannock1, C N Sternberg2.   

Abstract

Entities:  

Mesh：

Year:  2015        PMID： 26659397     DOI： 10.1093/annonc/mdv600

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  2 in total

Review 1.  Management algorithms for metastatic prostate cancer.

Authors:  Shawn Malone; Bobby Shayegan; Naveen S Basappa; Kim Chi; Henry J Conter; Robert J Hamilton; Sebastien J Hotte; Fred Saad; Alan I So; Laura Park-Wyllie; Huong Hew; Deanna McLeod; Geoffrey Gotto
Journal:  Can Urol Assoc J       Date:  2019-04-26       Impact factor: 1.862

2.  Comparison Between Prognostic Classifications in De Novo Metastatic Hormone Sensitive Prostate Cancer.

Authors:  Roberto Iacovelli; Chiara Ciccarese; Claudia Mosillo; Davide Bimbatti; Emanuela Fantinel; Lisa Stefani; Michele Simbolo; Mario Romano; Renzo Mazzarotto; Matteo Brunelli; Emilio Bria; Aldo Scarpa; Rita T Lawlor; Walter Artibani; Giampaolo Tortora
Journal:  Target Oncol       Date:  2018-10       Impact factor: 4.493
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.